PFE Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 май 2024 @ 23:00):

Stats
Объем за сегодня	45.37M
Средний объем	41.44M
Рыночная капитализация	157.04B
EPS	$0 ( 2024-05-01 )
Дата следующего отчета о доходах	( $0 ) 2024-07-30
Last Dividend	$0.410 ( 2023-11-09 )
Next Dividend	$0 ( N/A )
P/E	-556.20
ATR14	$0.0170 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Damico Jennifer B.	Buy	55	Phantom Stock Units SSP
2024-04-30	Bourla Albert	Buy	20	Phantom Stock Units SSP
2024-04-25	Quincey James	Buy	8 116	Phantom Stock Units
2024-04-25	Smith James C	Buy	8 116	Phantom Stock Units
2024-04-25	Nora Johnson Suzanne M	Buy	8 116	Phantom Stock Units

INSIDER POWER
70.76
Last 100 transactions
Buy: 4 322 762 \| Sell: 745 543

Объем Корреляция

Длинно: 0.64 (weak)

Кратко: 0.89 (strong)

Signal:(67.183) Same movement expected

Pfizer Inc Корреляция

10 Самые положительные корреляции
PCQ	0.969
ZME	0.962
CHGG	0.951
RSF	0.947
GDMA	0.946
TPL	0.941
CALX	0.939
EVTL	0.937
PCK	0.936
K	0.93

10 Самые отрицательные корреляции
WWW	-0.954
HCI	-0.953
NGL-PB	-0.95
FSNB	-0.949
LOCC	-0.949
LHC	-0.948
VNT	-0.947
CRH	-0.945
FTAI	-0.942
JMP	-0.94

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Pfizer Inc Корреляция - Валюта/Сырье

0.59
( weak )

0.79
( moderate )

0.00
( neutral )

-0.23
( neutral )

0.10
( neutral )

-0.85
( strong negative )

Pfizer Inc Финансовые показатели

Annual	2023
Выручка:	$58.50B
Валовая прибыль:	$29.28B (50.06 %)
EPS:	$0.380

FY	2023
Выручка:	$58.50B
Валовая прибыль:	$29.28B (50.06 %)
EPS:	$0.380

FY	2022
Выручка:	$100.33B
Валовая прибыль:	$65.99B (65.77 %)
EPS:	$5.59

FY	2021
Выручка:	$81.29B
Валовая прибыль:	$50.47B (62.08 %)
EPS:	$3.92

Financial Reports:

No articles found.

Pfizer Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.400 (N/A)	$0.400 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Pfizer Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 1.990 - low (50.00%) | Divividend Growth Potential Score: 2.67 - Decrease likely (46.58%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00316	1972-08-29
Last Dividend	$0.410	2023-11-09
Next Dividend	$0	N/A
Payout Date	2023-12-04
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$26.05	--
Avg. Dividend % Per Year	2.24%	--
Score	4.1	--
Div. Sustainability Score	1.990
Div.Growth Potential Score	2.67
Div. Directional Score	2.33	--

Next Divdend (Est)
(2024-07-01)

$0.413 Estimate 39.90 %

Dividend Stability

0.80 Good

Dividend Score

4.10

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.00731	0.90%
1973	$0.0138	1.60%
1974	$0.0156	1.83%
1975	$0.0160	2.52%
1976	$0.0170	3.03%
1977	$0.0196	3.44%
1978	$0.0231	4.27%
1979	$0.0261	3.98%
1980	$0.0285	3.84%
1981	$0.0316	3.01%
1982	$0.0364	3.50%
1983	$0.0460	3.43%
1984	$0.0524	3.66%
1985	$0.0584	3.65%
1986	$0.0648	3.27%
1987	$0.0712	2.91%
1988	$0.0792	4.13%
1989	$0.0868	3.81%
1990	$0.0948	3.37%
1991	$0.104	3.29%
1992	$0.117	1.77%
1993	$0.133	2.32%
1994	$0.149	2.77%
1995	$0.164	2.74%
1996	$0.190	1.93%
1997	$0.215	1.66%
1998	$0.240	1.00%
1999	$0.291	0.75%
2000	$0.342	1.13%
2001	$0.416	0.95%
2002	$0.492	1.30%
2003	$0.568	1.90%
2004	$0.644	1.91%
2005	$0.720	2.87%
2006	$0.912	4.04%
2007	$1.100	4.41%
2008	$1.216	5.59%
2009	$0.760	4.39%
2010	$0.684	3.81%
2011	$0.760	4.53%
2012	$0.836	4.01%
2013	$0.912	3.71%
2014	$0.988	3.42%
2015	$1.064	3.58%
2016	$1.140	3.76%
2017	$1.216	3.88%
2018	$1.292	3.74%
2019	$1.368	3.33%
2020	$1.444	3.89%
2021	$1.560	4.24%
2022	$1.600	2.82%
2023	$1.640	3.20%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.00561	1.500	-0.112	-0.168	[0 - 0.5]
returnOnAssetsTTM	-0.00136	1.200	-0.0455	-0.0546	[0 - 0.3]
returnOnEquityTTM	-0.00320	1.500	-1.147	-1.720	[0.1 - 1]
payoutRatioTTM	-29.93	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	0.907	0.800	-0.467	-0.373	[1 - 3]
quickRatioTTM	0.499	0.800	-1.768	-1.415	[0.8 - 2.5]
cashRatioTTM	0.0597	1.500	-0.779	-1.169	[0.2 - 2]
debtRatioTTM	0.320	-1.500	4.67	-7.01	[0 - 0.6]
interestCoverageTTM	0.531	1.000	-0.914	-0.914	[3 - 30]
operatingCashFlowPerShareTTM	1.538	2.00	9.49	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.847	2.00	9.58	10.00	[0 - 20]
debtEquityRatioTTM	0.814	-1.500	6.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.507	1.000	4.89	4.89	[0.2 - 0.8]
operatingProfitMarginTTM	0.0258	1.000	-1.483	-1.483	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.120	1.000	-0.444	-0.444	[0.2 - 2]
assetTurnoverTTM	0.243	0.800	-1.712	-1.369	[0.5 - 2]
Total Score				1.990

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-509.13	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.00320	2.50	-0.737	-1.720	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.847	2.00	9.72	10.00	[0 - 30]
dividendYielPercentageTTM	5.93	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.538	2.00	9.49	10.00	[0 - 30]
payoutRatioTTM	-29.93	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	23.65	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.158	1.000	8.55	0	[0.1 - 0.5]
Total Score				2.67

Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.